Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Rituximab for granulomatosis with polyangiitis or microscopic polyangiitis: a review of the clinical and cost-effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response. 2015 Authors' conclusions No evidence was identified that compared the clinical effectiveness of rituximab and cyclophosphamide and/or glucocorticoids for granulomatosis with polyangiitis or microscopic polyangiitis remission maintenance after remission induction with rituximab. Adverse event evidence from four identified uncontrolled, observational trials suggested that the most common serious adverse event was infection. Indexing Status Subject indexing assigned by CRD MeSH Microscopic Polyangiitiss Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: requests@cadth.ca AccessionNumber 32016000122 Date abstract record published 28/01/2016 |